AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 3NCT05261399Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have...AstraZeneca · CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 6, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT04068610COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCMedImmune LLC · Metastatic Microsatellite-stable Colorectal CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06376097Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.AstraZeneca · Lung CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 29, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT02546661Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerAstraZeneca · Muscle Invasive Bladder CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 18, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04157348Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.AstraZeneca · Eosinophilic Granulomatous VasculitisActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Aug 10, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04307953Saracatinib Trial TO Prevent FOPAmsterdam UMC, location VUmc · Fibrodysplasia Ossificans ProgressivaActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04999969Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or...AstraZeneca · Locally Advanced or Metastatic Solid TumoursActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 7, 2024Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05456867A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice...AstraZeneca · NSCLC, Non-small-cell Lung CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07218172Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)AstraZeneca · Severe AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07361276Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemAstraZeneca · HypertensionRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03449251A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxinCambridge University Hospitals NHS Foundation Trust · Cardiovascular DiseasesActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT03733535Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRIDr. Grace Parraga · Asthma; EosinophilicActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Mar 20, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT03903835ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerKarolinska Institutet · Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingJNJCollaboratorAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT03923270Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerH. Lee Moffitt Cancer Center and Research Institute · Small Cell Lung Cancer Extensive StageActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 1, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03965468Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCETOP IBCSG Partners Foundation · Non-small Cell Lung CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05000710Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapySheba Medical Center · Metastatic or Locally Advanced NSCLCActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05306743PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.Observational and Pragmatic Research Institute · Chronic Obstructive Pulmonary DiseaseRecruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05498272Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk...Rana McKay, MD · Prostate CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Aug 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06419179Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide...University of Cologne · Small Cell Lung CarcinomaEnrolling by invitationAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06489964Addressing Unfunded Vaccines Through a Co-payment Mechanism in PharmaciesCanadian Immunization Research Network · Preventable Disease, VaccineRecruitingAZNCollaboratorGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT03742245Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerThe Methodist Hospital Research Institute · Breast Cancer MetastaticActive, not recruitingMRKCollaboratorAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04417062Olaparib With Ceralasertib in Recurrent OsteosarcomaDana-Farber Cancer Institute · OsteosarcomaActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 1, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04745689Study of AZD2811 + Durvalumab in ES-SCLCAstraZeneca · Small-Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jun 18, 2022Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05817110Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.AstraZeneca · Lung MalignancyActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 6, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 87 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.